Gilead Sciences Inc. GILD
Super Investor & Insider
3
Fondi che lo detengono
#242
Rank consenso
4.3%
% dei portafogli
$3.41B
Valore detenuto
| Fondo | % portaf. | Attività | Azioni | Valore |
|---|---|---|---|---|
| Dodge & Cox · Dodge & Cox | 1.86% | Reduce 7.73% | 24,250,826 | $3.38B |
| John Rogers · Ariel Investments | 0.32% | Reduce 1.36% | 202,271 | $28.2M |
| Mairs & Power · Mairs & Power | 0% | — | 2,275 | $317,067 |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Gilead Sciences Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines addressing unmet medical needs in infectious diseases, oncology, and other therapeutic areas across the United States, Europe, and international markets. Its portfolio centers on HIV treatments, including leading …
SectorHealthcare
ExchangeNASDAQ
IndustryDrug Manufacturers - General
CountryUnited States
Employees17,000
TickerGILD
Statistics
Market Cap$154.78B
Revenue (TTM)$29.44B
Net Income$8.51B
Net Margin28.9%
EPS$6.78
P/E17.13
P/S5.26
P/B6.65
EV/EBITDA11.07
ROE43.4%
Dividend Yield2.61%
Price$124.62
Data: Twelve Data · Revenue = mcap / P/S